Caisse DE Depot ET Placement DU Quebec trimmed its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 0.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 679,796 shares of the company's stock after selling 6,067 shares during the quarter. Eli Lilly and Company comprises about 1.2% of Caisse DE Depot ET Placement DU Quebec's investment portfolio, making the stock its 12th biggest holding. Caisse DE Depot ET Placement DU Quebec owned about 0.07% of Eli Lilly and Company worth $602,258,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. International Assets Investment Management LLC increased its stake in Eli Lilly and Company by 87,091.7% during the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock valued at $11,041,631,000 after purchasing an additional 12,448,888 shares in the last quarter. Pathway Financial Advisers LLC increased its stake in Eli Lilly and Company by 92,759.9% during the 3rd quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company's stock valued at $905,774,000 after purchasing an additional 1,021,287 shares in the last quarter. Wulff Hansen & CO. increased its stake in Eli Lilly and Company by 90,438.0% during the 2nd quarter. Wulff Hansen & CO. now owns 937,068 shares of the company's stock valued at $848,403,000 after purchasing an additional 936,033 shares in the last quarter. Integrated Investment Consultants LLC increased its stake in Eli Lilly and Company by 37,140.7% during the 3rd quarter. Integrated Investment Consultants LLC now owns 694,167 shares of the company's stock valued at $614,990,000 after purchasing an additional 692,303 shares in the last quarter. Finally, Comerica Bank increased its stake in Eli Lilly and Company by 71.6% during the 2nd quarter. Comerica Bank now owns 1,512,983 shares of the company's stock valued at $1,369,825,000 after purchasing an additional 631,312 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.
Eli Lilly and Company Price Performance
Shares of LLY stock traded up $7.16 during mid-day trading on Friday, hitting $795.35. The company had a trading volume of 2,206,918 shares, compared to its average volume of 3,213,011. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53. The stock's 50 day moving average price is $851.90 and its 200-day moving average price is $870.26. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company has a market capitalization of $755.04 billion, a P/E ratio of 85.98, a P/E/G ratio of 2.99 and a beta of 0.43.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the firm posted $0.10 EPS. The company's revenue for the quarter was up 20.4% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 13.2 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company's dividend payout ratio is presently 56.22%.
Insider Buying and Selling
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on LLY shares. Evercore ISI upgraded shares of Eli Lilly and Company to a "hold" rating in a research note on Thursday, September 5th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a "buy" rating in a research note on Wednesday, August 14th. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 price target for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Friday, September 13th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,007.94.
Check Out Our Latest Stock Analysis on LLY
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report